

Naveni™ PD1/PD-L1

BRINGING PRECISION TO SPATIAL PROTEOMICS

Detect PD1/PD-L1 interactions *in situ*


Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed¹. PD-L1 IHC is commonly used as a biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear². Navinci has now developed the first commercial Proximity Ligation Assay for the specific detection of PD1/PD-L1 interactions *in situ*.

Naveni™ PD1/PD-L1 enables you to:


- Detect the specific interaction of PD1/PD-L1 using dual recognition
- Identify low-abundant PD1/PD-L1
- Visualize PD1/PD-L1 in the tissue microenvironment
- Increase understanding of PD1/PD-L1 signaling pathways
- Elucidate the potential of PD1/PD-L1 interaction as a predictive biomarker

Visit booth 54 and learn more!
Email: contact@navinci.se






The Naveni PPI PD1/PD-L1 kit is based on our proprietary Naveni™ Proximity Ligation Technology³. The kit includes two Navenibodies conjugated to proprietary oligo arms (depicted as orange antibodies in the illustration to the left). Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct dot.



PD1/PD-L1 interaction in the pancreatic ductal carcinoma, AP substrate



PD1/PD-L1 interaction in tonsil tissue, HRP substrate

Don't miss our poster presentations:

- Detection of the Proximity of PD1 and PD-L1 in Human FFPE Tissues using a Newly Developed Chromogenic in situ Proximity Ligation Assay, Poster session 1 (P1-391) 21st June, Agata Zieba Wicher, and
- Development of a Chromogenic in situ Proximity Ligation Assay for Detection of PD1/SHP2 Proximity in Human FFPE Tissues, Poster session 2 (P2-395) 22nd of June, Desireé Edén.

We will show off our newest products: Naveni pY PD1, for the detection of phosphorylated PD1, and Naveni PPI PD1/SHP2 for visualization of PD1 and SHP2 interactions.

Visit booth
54 and learn
more!

1. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nat Commun* 11, 3801 (2020).
2. Sánchez-Magrner L, et al., High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. *Cancer Res* 80, 19 (2020).
3. Klaesson A, et al., Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes. *Sci Rep.* 8(1):5400 (2018).



FOR MORE INFORMATION OR TO PLACE AN ORDER, VISIT WWW.NAVINCI.SE/PRODUCTS
Email: contact@navinci.se